Topline 12‑Month BIM‑IOL Phase 1/2 Results: IOP, Vision, Safety

Sponsor-reported topline 12-month results from a multicenter, randomized Phase 1/2 trial describe the BIM‑IOL System (a bimatoprost drug pad–IOL system with non-bioerodible drug pads attached to an intraocular lens) in people with open-angle glaucoma or ocular hypertension undergoing cataract surgery. In the company’s press release, the main themes were sustained intraocular pressure (IOP) lowering and high rates of discontinuation of topical IOP-lowering medication, with postoperative visual outcomes described as consistent with standard intraocular lens expectations.

The press release describes the study as prospective, multicenter, randomized, double-masked, and controlled, with 2:1:1 allocation. Participants were assigned to a 78 mcg BIM‑IOL arm (N=51) or a 39 mcg BIM‑IOL arm (N=23), each paired with daily administration of artificial tear drops, or to a control arm that received a commercially available monofocal IOL plus twice-daily topical timolol (N=30). Total enrollment was reported as 104 randomized patients, and the control IOLs were sourced from multiple manufacturers (Alcon, Bausch + Lomb, or Johnson & Johnson) per the release. The primary endpoint is described as mean IOP reduction from baseline at prespecified follow-up timepoints, assessed at two time points for each follow-up visit at 2 weeks, 6 weeks, and 3 months. Overall, the trial structure positioned the BIM‑IOL dose arms against an IOL-plus-topical-therapy comparator under masked, controlled conditions.

At 12 months, the release reports mean IOP reductions from baseline at the 8 a.m. timepoint of 34% in the 78 mcg group and 42% in the 39 mcg group, compared with 35% in the control group; it also notes similar results at the 10 a.m. timepoint. Medication-sparing outcomes were presented for evaluable patients in the BIM‑IOL arms: 98% (48/49) in the 78 mcg arm and 96% (22/23) in the 39 mcg arm were reported as free from all topical IOP-lowering medications. The press release frames these topline efficacy findings as IOP reduction maintained through the 12-month readout alongside near-universal topical-therapy discontinuation among evaluable BIM‑IOL recipients.

Postoperative visual outcomes were summarized for evaluable BIM‑IOL patients, with the release stating that 100% (N=72 evaluable) achieved best corrected distance visual acuity of 20/32 or better and that mean acuity was 86 ETDRS letters, described as equivalent to 20/20. On safety, the company reported adverse event rates of 41.2% in the 78 mcg arm, 43.5% in the 39 mcg arm, and 36.7% in the control arm, characterizing these rates as similar across groups, and it stated that no serious ocular adverse events were observed. The release further characterizes overall safety results as comparable to routine cataract surgery.

The BIM‑IOL platform is described as proprietary, with non-bioerodible drug pads attached to an intraocular lens and designed to consistently deliver multiple years of bimatoprost, a prostaglandin analog approved for topical use for IOP reduction. For next steps, the company states that it has initiated two identical registrational Phase 3 trials evaluating the 78 mcg dose, noting that the Phase 3 design is largely consistent with the Phase 1/2 trial with minor protocol modifications intended to improve consistency across trial arms. The press release also states an intent to work with the FDA toward a 505(b)(2) New Drug Application submission, while continuing long-term follow-up in prior studies and enrollment in ongoing Phase 3 trials. As positioned by the company, the topline Phase 1/2 readout is intended to support the transition into registrational studies and related regulatory planning.

Key Takeaways:

• The sponsor reported 12-month IOP reduction and medication-free outcomes in both BIM‑IOL dose arms in a randomized Phase 1/2 cataract-surgery population with OAG or ocular hypertension.
• In sponsor-reported topline data, evaluable patients had 100% achieving best corrected distance visual acuity of 20/32 or better, and adverse event rates were similar across groups with no serious ocular adverse events reported.
• The press release describes a non-bioerodible drug pad–IOL platform intended for multi-year bimatoprost delivery and outlines Phase 3 and regulatory pathway plans.